title: Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation.
abstract: OBJECTIVE
  To evaluate the effects of cancer on ovarian response in controlled ovarian hyperstimulation (COH).
  
  
  METHODS
  Retrospective analysis study.
  
  
  METHODS
  University-based tertiary medical center.
  
  
  METHODS
  81 cancer patients undergoing controlled ovarian stimulation cycles for fertility preservation, and age- and date-matched controls undergoing COH for in vitro fertilization (IVF) for male factor infertility.
  
  
  METHODS
  Controlled ovarian hyperstimulation and oocytes retrieval.
  
  
  METHODS
  Maximal estradiol levels at day of human chorionic gonadotropin administration, duration of stimulation, total amount of gonadotropins administered, number of dominant follicles, number of oocytes retrieved, and rate of metaphase 2 oocytes.
  
  
  RESULTS
  The overall number of dominant follicles and the number of oocytes aspirated of the study group and control were comparable (8.8 ± 5.3 vs. 9.7 ± 4.9, and 11.93 ± 8.3 vs. 12.3 ± 7.9, respectively). The total dose of gonadotropins used and number of stimulation days of the study group (2,250 IU [1,800-3,000 IU] and 9.5 [8-11]) were also similar to the controls (2,100 IU [1,700-2,900] and 10 [9-13]). Comparison between four subgroups of cancer-breast cancer, soft tissue sarcoma, hematologic malignancies, and gastrointestinal tract cancers-showed no difference in their ovarian response indexes. Regression analysis to assess the effect of cancer on ovarian response showed no effect on the main outcome measured.
  
  
  CONCLUSIONS
  Cancer does not influence ovarian response in COH for fertility preservation.
authors: Sarah Racine IVF Unit, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel. bennyalmo@gmail.com
authors: Benny
authors: B
authors: Almog
authors: Foad
authors: F
authors: Azem
authors: David
authors: D
authors: Gordon
authors: David
authors: D
authors: Pauzner
authors: Ami
authors: A
authors: Amit
authors: Gali
authors: G
authors: Barkan
authors: Ishai
authors: I
authors: Levin
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000150:complications; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D004958:Estradiol / Q000097:blood; D005260:Female; D059247:Fertility Preservation / Q000379:methods*; D005307:Fertilization in Vitro; D005770:Gastrointestinal Neoplasms / Q000150:complications; D019337:Hematologic Neoplasms / Q000150:complications; D006801:Humans; D007246:Infertility / Q000628:therapy*; D008297:Male; D009369:Neoplasms / Q000150:complications*; D054315:Oocyte Retrieval / Q000379:methods; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D012102:Reproductive Control Agents / Q000008:administration & dosage; D012189:Retrospective Studies; D012983:Soft Tissue Neoplasms / Q000150:complications
chemical_list: D006063:Chorionic Gonadotropin; D012102:Reproductive Control Agents; D004958:Estradiol